Skip to main content
. 2016 Oct 19;6:35561. doi: 10.1038/srep35561

Figure 6. Analysis of PCNA subcellular localization in blast cells from patients with AML.

Figure 6

(a) Subcellular localization of PCNA in primary leukemic cells from patients with acute myeloid leukemia (AML). Immunofluorescence analysis by confocal microscopy of PCNA localization in blasts of AML patients with NK or CBF and in normal human CD34+ HPs using the rabbit polyclonal antibody Ab5 and Hoechst for nuclear labeling. Panel a shows a representative experiment of three, all yielding the same results. (b) Distribution of cytoplasmic or nuclear PCNA in blasts from AML patients according to the cytogenetic characterization. PCNA localization was determined in a cohort of 50 AML patients. The histogram depicts the percentages of AML patients showing either cytoplasmic or nuclear PCNA. (c) Immunofluorescence analysis by confocal microscopy of PCNA localization (performed as in a) in blasts from one AML patients after LMB treatment. Panel c shows a representative experiment of three yielding the same results. (d) Effect of the p21-peptide-YIRS on viability of blasts from 5 AML patients including 4 patients with cytosolic (open circle) and 1 patient with nuclear (dark triangle) PCNA. Blast cells were cultured for 16 h at 37 °C with or without the p21-peptide-YIRS (50 μM) and annexinV-7AAD-positive cells measured by flow cytometry.